A compact Western European market with deep university hospital networks, strong Phase I capability, EU CTR alignment, and a dense CRO and life sciences ecosystem for sponsors evaluating regional trial strategy.
Belgium is a small, densely populated federal state of 11.6 million people at the heart of Western Europe; bordered by France, the Netherlands, Germany, Luxembourg, and the North Sea. Despite its compact size, Belgium is the headquarters of the European Union, NATO, and scores of international pharmaceutical and biotechnology companies, making Brussels one of the world's most important life sciences policy and commercial hubs. The country is home to globally significant pharma companies including UCB, Galapagos, and major European offices of Johnson & Johnson (Janssen), GSK, AstraZeneca, Pfizer, and Novartis.
Clinical trials are regulated by FAMHP (Federal Agency for Medicinal Products and Health Products) under the EU Clinical Trials Regulation (CTR) framework, with ethics oversight provided by recognized ethics committees at Belgium's university hospitals. Belgium has ranked in the top 2 for clinical trials per capita in Europe; after Denmark and Estonia; for over a decade, with 474 clinical trial authorizations in 2022 (80% company-initiated), over 1,500 trials running simultaneously in 2017, and 135 active CROs generating €283.9 million in added value in 2021; a 30% increase versus 2018.
Belgium's 11.6 million people are divided across three linguistic communities; Dutch-speaking Flanders (north), French-speaking Wallonia (south), and Brussels (bilingual). This federal structure shapes the research landscape: Flanders (KU Leuven, UGent, UAntwerp) and Wallonia (UCLouvain, ULiège) each have world-class university hospital networks with distinct research strengths and investigator communities. Belgium's population is homogeneous enough for clean European-ancestry trial data, while the country's large immigrant communities (particularly from North Africa and Turkey) are adding diversity to clinical cohorts.
Belgium's universal healthcare system ensures broad patient access and comprehensive health records, facilitating patient identification and long-term follow-up. The country's high physician density and strong academic culture mean that investigators are plentiful, highly trained, and deeply familiar with ICH-GCP standards from years of industry collaboration.
The Phase I strength: Belgium is one of Europe's strongest Phase I markets; one-third of all Phase I clinical trials in Belgium are first-in-human studies. This reflects the depth of Belgium's early-phase infrastructure: 7 university hospitals, 12 universities with life sciences faculties, 14 bioincubators, and 52 companies active in clinical R&D, all operating within a regulatory framework that industry rates highly for scientific expertise and quality.
Belgium's long-standing position as Europe's top-2 trial market per capita is not accidental; it reflects decades of accumulated scientific expertise, regulatory quality, and industry trust. The FAMHP is consistently rated by sponsors as one of Europe's most scientifically rigorous and practically efficient competent authorities. Belgium's central location within the EU, its multilingual research workforce, and its concentration of pharma industry headquarters make it the natural choice for European program anchoring.
FAMHP consistently rated among Europe's best NCAs for scientific rigor; full EU CTR/CTIS integration; quarterly updated online dashboard for all CTR submissions; ethics committees embedded in university hospitals; strong regulatory-industry dialogue culture.
135 active CROs (€283.9M added value, +30% vs 2018); EU HQ for J&J (Janssen), GSK, AstraZeneca, UCB, Galapagos, Pfizer; 14 bioincubators; 52 clinical R&D companies; VIB Flanders Institute for Biotechnology; EU and NATO headquarters; unmatched policy proximity.
Universal healthcare with comprehensive records; high physician density; GCP-trained investigator community with decades of industry experience; 80% company-initiated trials signals strong sponsor-site trust; 8% of CTAs include paediatric investigation plans.
7 university hospitals; 12 universities with life sciences faculties; 14 bioincubators; top-2 EU per capita for over a decade; one-third of Phase I are FIH; broad therapeutic area coverage; strong rare disease capability (FAMHP data); oncology steady growth.
Belgium covers virtually all therapeutic areas but has particular strengths in oncology (steady CTA growth, though slightly down in 2024 vs the EU cohort), rare diseases, cardiovascular, CNS, and paediatrics. Phase I first-in-human is a genuine Belgian specialty; reflecting the confidence sponsors place in Belgian sites for high-stakes early research. The country's strong biotech ecosystem (VIB, Flanders bioincubators) feeds a steady pipeline of novel molecules into Belgian investigator-initiated and industry-sponsored Phase I programs.
Belgium's university hospital network; anchored in Leuven, Ghent, Brussels, Liège, and Antwerp; forms the backbone of the country's clinical research ecosystem. All major university hospitals operate internationally recognized research departments with decades of industry trial experience. Brussels also hosts several independent research centres and CRO-affiliated Phase I units.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | UZ Leuven; University Hospitals Leuven | Leuven | KU Leuven affiliate; Belgium's most research-active university hospital; Phase I–IV across oncology, cardiovascular, rare disease, and neurology; one of Europe's leading oncology research centers; strong FIH program; multi-disciplinary trial teams; 700+ researchers. |
| 02 | UZ Gent; Ghent University Hospital | Ghent | Ghent University affiliate; Phase I–IV across oncology, cardiovascular, and rare diseases; strong hematology and bone marrow transplantation program; VIB-affiliated research groups; major Flemish patient catchment; growing FIH and early-phase oncology program. |
| 03 | UZ Brussel; Brussels University Hospital (VUB) | Brussels | Vrije Universiteit Brussel affiliate; Phase I–IV across oncology, immunology, and cardiovascular; Brussels metropolitan patient access; strong autoimmune and inflammatory disease research; growing FIH program; proximity to EU institutions and pharma Brussels offices. |
| 04 | Erasme Hospital; ULB | Brussels | Université Libre de Bruxelles affiliate; Phase I–IV across oncology, hepatology, and cardiovascular; major Francophone Belgium research hospital; liver disease and gastroenterology specialist; strong Phase II–III commercial portfolio; Brussels south patient catchment. |
| 05 | CHU de Liège; University Hospital of Liège | Liège | University of Liège affiliate; Phase I–IV across oncology, cardiovascular, and neurology; Eastern Belgium and German-border region patient access; GIGA research institute partnership; growing FIH early-phase oncology program. |
| 06 | UZA; Antwerp University Hospital | Antwerp | University of Antwerp affiliate; Phase I–IV across oncology, tropical medicine, and cardiovascular; ITM (Institute of Tropical Medicine) partnership; unique infectious disease and global health research capacity; port city patient diversity; growing commercial Phase II–III portfolio. |
| 07 | Institut Jules Bordet | Brussels | Belgium's dedicated national cancer center (ULB affiliated); Phase I–IV oncology specialist; breast, lung, and hematologic malignancy focus; ESMO-accredited center of excellence; major FIH oncology program; strong translational research pipeline. |
| 08 | CHU UCL Namur; Université Catholique de Louvain | Namur | UCLouvain affiliate; Phase II–IV across oncology, cardiovascular, and diabetes; Walloon Belgium patient access; growing commercial research portfolio; strong academic-industry collaboration in central Belgium. |
| 09 | AZ Sint-Jan Brugge; AZ Delta | Bruges | Leading non-university hospital research center; Phase II–III across oncology, cardiovascular, and metabolic disease; West Flanders patient access; strong community-hospital commercial trial track record; efficient startup and enrollment. |
| 10 | ZNA; Ziekenhuis Netwerk Antwerpen | Antwerp | Antwerp hospital network; Phase II–IV across oncology, cardiovascular, and infectious disease; access to Antwerp's diverse metropolitan patient population; growing commercial research portfolio; efficient site management teams. |
| 11 | Cliniques Universitaires Saint-Luc (UCLouvain) | Brussels | UCLouvain Brussels university hospital; Phase I–IV across oncology, transplantation, and cardiovascular; strong organ transplantation research program; Brussels Francophone patient access; FIH and early-phase oncology capability. |
| 12 | Hôpital Erasme / CHIREC Cancer Institute | Brussels | Brussels private oncology research center; Phase II–III oncology trials; breast, lung, and colorectal cancer focus; strong industry-sponsored commercial portfolio; efficient contracting and startup times; Brussels south patient access. |
KU Leuven affiliate; Belgium's most research-active university hospital; Phase I–IV across oncology, cardiovascular, rare disease, and neurology; one of Europe's leading oncology research centers; strong FIH program; multi-disciplinary trial teams; 700+ researchers.
Ghent University affiliate; Phase I–IV across oncology, cardiovascular, and rare diseases; strong hematology and bone marrow transplantation program; VIB-affiliated research groups; major Flemish patient catchment; growing FIH and early-phase oncology program.
Vrije Universiteit Brussel affiliate; Phase I–IV across oncology, immunology, and cardiovascular; Brussels metropolitan patient access; strong autoimmune and inflammatory disease research; growing FIH program; proximity to EU institutions and pharma Brussels offices.
Université Libre de Bruxelles affiliate; Phase I–IV across oncology, hepatology, and cardiovascular; major Francophone Belgium research hospital; liver disease and gastroenterology specialist; strong Phase II–III commercial portfolio; Brussels south patient catchment.
University of Liège affiliate; Phase I–IV across oncology, cardiovascular, and neurology; Eastern Belgium and German-border region patient access; GIGA research institute partnership; growing FIH early-phase oncology program.
University of Antwerp affiliate; Phase I–IV across oncology, tropical medicine, and cardiovascular; ITM (Institute of Tropical Medicine) partnership; unique infectious disease and global health research capacity; port city patient diversity; growing commercial Phase II–III portfolio.
Belgium's dedicated national cancer center (ULB affiliated); Phase I–IV oncology specialist; breast, lung, and hematologic malignancy focus; ESMO-accredited center of excellence; major FIH oncology program; strong translational research pipeline.
UCLouvain affiliate; Phase II–IV across oncology, cardiovascular, and diabetes; Walloon Belgium patient access; growing commercial research portfolio; strong academic-industry collaboration in central Belgium.
Leading non-university hospital research center; Phase II–III across oncology, cardiovascular, and metabolic disease; West Flanders patient access; strong community-hospital commercial trial track record; efficient startup and enrollment.
Antwerp hospital network; Phase II–IV across oncology, cardiovascular, and infectious disease; access to Antwerp's diverse metropolitan patient population; growing commercial research portfolio; efficient site management teams.
UCLouvain Brussels university hospital; Phase I–IV across oncology, transplantation, and cardiovascular; strong organ transplantation research program; Brussels Francophone patient access; FIH and early-phase oncology capability.
Brussels private oncology research center; Phase II–III oncology trials; breast, lung, and colorectal cancer focus; strong industry-sponsored commercial portfolio; efficient contracting and startup times; Brussels south patient access.
These are the primary regulatory, academic, and industry bodies shaping Belgium's clinical research ecosystem.
National competent authority; top-rated by sponsors for scientific expertise; full EU CTR/CTIS integration; quarterly updated online dashboard; collaborative regulatory-industry dialogue culture; consistent top-2 EU per capita ranking for 10+ years.
Industry body; annual 'Belgium as a Clinical Trial Location in Europe' Deloitte report (benchmark data); advocacy for decentralized trials and real-world data; 135 active CRO members; bridges FAMHP, university hospitals, and international sponsors.
Belgium's leading research university; UZ Leuven affiliate; world-ranked oncology, cardiovascular, and rare disease research; VIB partnership; major source of investigator-initiated Phase I programs; drives Belgium's FIH strength.
Life sciences research institute; drug discovery pipeline; cancer, neurodegenerative disease, and inflammation specialty; 14 bioincubator partners; feeds novel molecule pipeline into Phase I programs at UZ Leuven, UZ Gent, and UZA.
National public health institute; epidemiology and infectious disease research; COVID-19 trial coordination; vaccine research; health data infrastructure; supports real-world evidence generation for Belgian trial data.
Largest CRO footprint in Belgium; FAMHP regulatory expertise; university hospital site networks; Phase I–IV management; data analytics and real-world evidence; regional Benelux hub for European programs.
Global CRO with Belgium operations; oncology and rare disease specialty; FAMHP submissions; connecting international sponsors with Belgian university hospital networks; Phase I–IV management.
Global CRO with Belgian presence; Phase I early-phase specialist including FIH; FAMHP regulatory expertise; oncology, CNS, and cardiovascular specialty.
Belgium is one of Western Europe's most concentrated clinical research markets. Its strength comes from the combination of university hospitals, early-phase capability, regulatory maturity, CRO density, and strong life sciences infrastructure. For sponsors and CROs planning European programs, Belgium offers a compact but highly capable environment for patient access, investigator quality, and trial delivery.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.